• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by GSK plc

    11/12/24 4:32:59 PM ET
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GSK alert in real time by email
    SC 13G/A 1 wavelife-sc13ga_093024.htm AMENDMENT TO FORM SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

    Wave Life Sciences Ltd. 

    (Name of Issuer)

     

    $0 Par Value Ordinary Share

    (Title of Class of Securities)

      

    Y95308105

    (CUSIP Number)

     

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    Persons who respond to the collection of information contained in this form are not
    required to respond unless the form displays a currently valid OMB control number.

     

     

     

     

     

    13G/A2

     

    CUSIP No. Y95308105
     

    1. Names of Reporting Persons.

     

          GSK plc

    2. Check the Appropriate Box if a Member of a Group

    (a) ☐

    (b) ☐

     

    3. SEC Use Only
    4. Citizenship or Place of Organization
    England and Wales
    Number of Shares
    Beneficially
    Owned by
    Each Reporting
    Person With:
    5. Sole Voting Power
    16,775,691 (1)
    6. Shared Voting Power
    0
    7. Sole Dispositive Power
    16,775,691 (1)
    8. Shared Dispositive Power
    0

    9. Aggregate Amount Beneficially Owned by Each Reporting Person

    16,775,691 (1)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares ☐
    11. Percent of Class Represented by Amount in Row (9)
    11.2% (2)
    12. Type of Reporting Person
    CO

     

    (1) Ordinary Shares (as defined below) are held of record by Glaxo Group Limited, a wholly-owned subsidiary of the Reporting Person.

     

    (2) Based upon 149,354,290 Ordinary Shares outstanding after the Issuer’s offering, as reported in the Issuer’s prospectus supplement dated September 25, 2024, which includes the exercise of the underwriters’ option to purchase additional Ordinary Shares, as reported in the Issuer’s Press Release on October 1, 2024.

     

     

     

     

    13G/A2

    CUSIP No. Y95308105

     

    ITEM 1.

    (a) Name of Issuer:

    Wave Life Sciences Ltd. (the “Issuer”)

     

    (b)Address of Issuer’s Principal Executive Offices:

    7 Straits View #12-00

    Marina One, East Tower

    Singapore 018936

     

    ITEM 2.

    (a) Name of Person Filing:

    GSK plc

     

    (b) Address of Principal Business Office, or if None, Residence:

    79 New Oxford Street

    London

    WC1A 1DG

    England

     

    (c)Citizenship:

    England and Wales

     

    (d)Title of Class of Securities:

    $0 Par Value Ordinary Shares (the “Ordinary Shares”)

     

    (e)CUSIP Number:

    Y95308105

     

    ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SS.240.13d-1(b) OR 240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

    Not Applicable

     

    ITEM 4. OWNERSHIP.

     

    The information in items 1 and 5 through 11 on the cover page of this Schedule 13G is hereby incorporated by reference.

      

    ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

     

    ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.

     

    Glaxo Group Limited* 16,775,691 11.2%

     

    *Shares are held of record by Glaxo Group Limited, an indirect wholly-owned subsidiary of the Reporting Person.

     

     

     

     

    13G/A2

     

    CUSIP No. Y95308105

     

    ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.

     

    Not Applicable

     

    ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.

     

    Not Applicable

     

    ITEM 9. NOTICE OF DISSOLUTION OF GROUP.

     

    Not Applicable

      

    ITEM 10. CERTIFICATIONS.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. 

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: November 12, 2024

            

      GSK plc
       
      By: /s/ Victoria A. Whyte  
        Victoria A. Whyte
        Authorized Signatory

     

     

     

    Get the next $GSK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GSK

    DatePrice TargetRatingAnalyst
    4/15/2025$35.25Neutral
    Exane BNP Paribas
    2/12/2025Equal-Weight
    Morgan Stanley
    11/15/2024Buy → Hold
    Deutsche Bank
    11/12/2024$53.00 → $39.50Buy → Hold
    Jefferies
    10/31/2024Buy → Neutral
    Guggenheim
    7/8/2024Buy → Neutral
    UBS
    5/30/2024$47.00Neutral
    Goldman
    3/4/2024Neutral → Buy
    Guggenheim
    More analyst ratings

    $GSK
    SEC Filings

    See more
    • SEC Form 6-K filed by GSK plc

      6-K - GSK plc (0001131399) (Filer)

      5/8/25 11:26:51 AM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by GSK plc

      6-K - GSK plc (0001131399) (Filer)

      5/8/25 9:37:24 AM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by GSK plc

      6-K - GSK plc (0001131399) (Filer)

      5/8/25 6:49:05 AM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GSK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer's Disease

      --76-week trial is evaluating the safety and efficacy of a progranulin-elevating candidate in slowing disease progression-- --Enrollment completed ahead of schedule-- SOUTH SAN FRANCISCO, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced the completion of enrollment in PROGRESS-AD, a 76-week Phase 2 clinical trial evaluating the safety and efficacy of AL101/GSK4527226 in slowing disease progression in individuals with early Alzheimer's disease (AD). Alector and GSK are co-developing AL101, an investigational hum

      4/17/25 8:00:00 AM ET
      $ALEC
      $GSK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • AREXVY recommended for adults aged 50-59 at increased risk for severe respiratory syncytial virus (RSV) disease by US Advisory Committee on Immunization Practices

      Over 13 million adults aged 50-59 at increased risk in the US can potentially benefit from RSV immunization1 RSV causes an estimated 42,000 hospitalizations* each year in adults aged 50-64 years old in the US2 GSK plc (LSE/NYSE:GSK) is pleased that the Advisory Committee on Immunization Practices (ACIP) voted in favor of recommending the use of RSV vaccines including GSK's AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) in adults aged 50-59 who are at increased risk for severe RSV disease. This includes people with conditions like COPD, asthma, diabetes, heart disease and those in residential care3. This expands on ACIP's previous vote in June 2024 to recommend RSV vaccines fo

      4/16/25 5:36:00 PM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GSK's 5-in-1 Meningococcal Vaccine PENMENVY Receives Positive Recommendation from US Advisory Committee on Immunization Practices

      Vaccine recommended to help protect persons over 10 years old in the United States (US) against disease-causing serogroups of Neisseria meningitidis (A, B, C, W, and Y) Broad serogroup coverage in one vaccine reduces injections to help improve vaccination rates and help protect more US adolescents and young adults Vaccine doses will be ready for use in the US from Summer 2025 GSK plc (LSE/NYSE:GSK) today announced that the US Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) has voted to recommend use of PENMENVY (Meningococcal Groups A, B, C, W, and Y Vaccine) as part of the adolescent meningococcal vaccination schedule. Recommend

      4/16/25 4:57:00 PM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GSK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Exane BNP Paribas initiated coverage on GlaxoSmithKline with a new price target

      Exane BNP Paribas initiated coverage of GlaxoSmithKline with a rating of Neutral and set a new price target of $35.25

      4/15/25 12:40:46 PM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morgan Stanley initiated coverage on GlaxoSmithKline

      Morgan Stanley initiated coverage of GlaxoSmithKline with a rating of Equal-Weight

      2/12/25 7:05:11 AM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GlaxoSmithKline downgraded by Deutsche Bank

      Deutsche Bank downgraded GlaxoSmithKline from Buy to Hold

      11/15/24 7:46:43 AM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GSK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: GLAXOSMITHKLINE PLC converted options into 700,772 units of Common Stock and bought $4,950,000 worth of Common Stock (275,000 units at $18.00)

      4 - GLAXOSMITHKLINE PLC (0001131399) (Reporting)

      7/6/21 4:38:14 PM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by GLAXOSMITHKLINE PLC

      3 - GLAXOSMITHKLINE PLC (0001131399) (Reporting)

      7/6/21 4:22:59 PM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: GLAXOSMITHKLINE PLC converted options into 30,253,189 units of Common Stock

      4 - GLAXOSMITHKLINE PLC (0001131399) (Reporting)

      6/23/21 6:14:59 PM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GSK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by GSK plc

      SC 13G/A - GSK plc (0001131399) (Subject)

      11/12/24 4:32:59 PM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by GSK plc (Amendment)

      SC 13G/A - GSK plc (0001131399) (Subject)

      2/13/24 1:37:25 PM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by GSK plc (Amendment)

      SC 13G/A - GSK PLC (0001131399) (Subject)

      2/14/23 1:54:01 PM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GSK
    Financials

    Live finance-specific insights

    See more
    • Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%

      Highlights Second quarter revenue grew 15% year-over-year to $212 million, driven by Prenatal (25%), Pharmacogenomics (22%), and Hereditary Cancer (19%).Second quarter GAAP earnings per share improved to $(0.41) from $(1.42) in the second quarter of 2023; adjusted earnings per share improved to $0.05 from $(0.08) in the second quarter of 2023.Increasing 2024 financial guidance with full year revenue moving to a range of $835 - $845 million, or an annual growth rate of between 11% and 12%, and increasing adjusted earnings per share (EPS) to a range of $0.08 - $0.12.1 _________________________1 The company does not forecast GAAP EPS because it cannot predict certain elements that are include

      8/6/24 4:05:00 PM ET
      $GSK
      $MYGN
      $PSNL
      $QGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Medical Specialities
    • GSK and CureVac to Restructure Collaboration into New Licensing Agreement

      GSK acquires full rights to develop, manufacture and commercialize globally mRNA candidate vaccines for influenza and COVID-19, including combinationsCureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replacedLONDON, UK, TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / July 3, 2024 / GSK plc (NYSE:GSK) and CureVac N.V. (NASDAQ:CVAC) today announced they have restructured their existing collaboration into a new licensing agreement, allowing each company to prioritize investment and focus their respective mRNA

      7/3/24 2:40:00 AM ET
      $CVAC
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 23andMe Reports Third Quarter Fiscal 2024 Financial Results

      SOUTH SAN FRANCISCO, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME), a leading human genetics and biopharmaceutical company, reported its financial results for the third quarter of fiscal year 2024 (FY24), which ended December 31, 2023. Key Results Reported total revenue of $44.7 million in the third quarter of fiscal 2024, compared to $66.9 million in the third quarter of fiscal 2023, a decrease of approximately 33% due to lower research revenue after the conclusion of the GSK collaboration exclusivity term in July 2023 and lower PGS kit volumes.Announced a non-exclusive data license with GSK plc (NYSE:GSK) for novel drug target discovery and other research. U

      2/7/24 4:01:00 PM ET
      $GSK
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GSK
    Leadership Updates

    Live Leadership Updates

    See more
    • GeminiBio Appoints Mike Stella to Board

      Strengthening Board with Industry Veterans Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Fort Lauderdale-based healthcare private equity firm, announced today the appointment of Michael Stella to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218608576/en/Mike Stella, CEO of Ascend Advanced Therapies, joins the Board at GeminiBio to provide strategic leadership in the fields of cell and gene therapy contract development and manufacturing. (Photo: Business Wire) GeminiBio prov

      2/18/25 9:00:00 AM ET
      $AMGN
      $GSK
      $JNJ
      $MRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Industrial Machinery/Components
    • Medicus Pharma Ltd. Appoints Faisal Mehmud, MD, MRCP as Chief Medical Officer

      TORONTO and PHILADELPHIA, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd (NASDAQ:MDCX, TSXV:MDCX) (the "Company") is pleased to announce the appointment of Faisal Mehmud, MD as Chief Medical Officer. "We are thrilled to welcome Dr. Mehmud to our leadership team," stated Dr. Raza Bokhari, Exec. Chairman & CEO. "Faisal has a proven track record in integrating cutting-edge science with practical, evidence-based medical strategies to develop partnerships and launch high impact therapies. We aim to capitalize on his experience and expertise to expand our drug development pipeline and foster collaboration with strategic partners to bring to market our novel non-invasive patented dissolvab

      11/18/24 7:30:00 AM ET
      $GSK
      $MDCX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spero Therapeutics Appoints Sath Shukla as President & Chief Executive Officer

      Sath Shukla, current Spero Chief Financial Officer, will bring more than 20 years of strategic and financial leadership to the role of CEO, to be effective August 1, 2023 Current President and Chief Executive Officer, Ankit Mahadevia, M.D to become Chairman of the Board of Directors CAMBRIDGE, Mass., June 14, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Satyavrat "Sath" Shukla, Spero's current Chief Financial Officer and Treas

      6/14/23 8:05:00 AM ET
      $GSK
      $PFE
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care